📰 What This Document Is 🔬

This document is a Form 6-K filing (an international filing required by the SEC) that serves as a press release. It communicates critical clinical data results from Alterity Therapeutics' lead drug candidate, ATH434. Essentially, Alterity presented new, detailed findings about ATH434's effectiveness in a major medical conference, and they shared those findings with the public.

👉 The headline finding is that ATH434 showed consistent evidence of slowing functional decline in patients with Multiple System Atrophy (MSA) during a Phase 2 clinical trial.

🏥 What Is Multiple System Atrophy (MSA)? 🧠

Multiple System Atrophy (MSA) is a rare and serious neurodegenerative disease. It involves the progressive loss of function and death of different types of nerve cells in the brain and spinal cord. This loss of nerve function leads to profound disability, affecting movement, balance, and involuntary functions like bladder control.

👉 MSA is a rapidly progressing condition, and while some symptoms can be managed with medication, currently, there are no drugs available that can slow the disease's progression or act as a cure.

🧬 How ATH434 Works 🛠️

ATH434 is Alterity's primary drug candidate, which is administered as an oral agent. Its mechanism of action is designed to tackle the underlying causes of neurodegeneration. It works by reducing iron accumulation and inhibiting abnormal protein aggregation within the central nervous system.

👉 By acting as an "iron chaperone," ATH434 aims to restore normal iron balance in the brain. This mechanism gives it potential applications not only for MSA but also for other related Parkinsonian disorders, such as Parkinson's disease.

🦠 The Clinical Trial Data Breakthrough 📊

The core of the filing focuses on data derived from the ATH434-201 Phase 2 clinical trial in MSA. Alterity presented these results at the American Academy of Neurology (AAN) Annual Meeting, using two key assessment scales: MuSyCA and modified UMSARS I.

MuSyCA Assessment (New Composite Scale)

The MuSyCA is a novel outcome assessment scale that is particularly useful because it integrates two types of information: patient-reported function (daily activities) and objective clinical examination (motor skills). This combined approach helps detect disease progression more effectively than older methods.

• Assessment Finding: The scale showed that placebo participants deteriorated by approximately +9.7 points over 52 weeks, confirming its high sensitivity to disease progression.
• ATH434 Efficacy (MuSyCA): ATH434 successfully slowed disease progression.
  • At the 75 mg dose, the treatment effect was measured at −1.9 points.
  • At the 50 mg dose, the treatment effect was measured at −4.0 points at Week 52 (p=0.034), showing a relative treatment effect of 41%.

Modified UMSARS I Assessment (Established Scale)

The study also used the modified UMSARS I scale, which measures daily function and is a more established tool. The use of the MMRM 3 statistical analysis was employed for this comparison.

• ATH434 Efficacy (UMSARS I): ATH434 showed robust slowing of functional decline compared to placebo.
  • At the 75 mg dose, the relative treatment effect was 35% (a reduction of -3.1 points).
  • At the 50 mg dose, the relative treatment effect was 53% (a reduction of -4.7 points) (p=0.029).

🧑‍🔬 Expert Commentary and Significance 💬

The company's CEO, David Stamler, provided commentary that summarizes the clinical significance of these combined results.

• David Stamler, CEO of Alterity, commented: "In this rapidly progressive disease, ATH434 shows consistent evidence of efficacy by slowing functional decline on the newly described MuSyCA scale, which reinforces the efficacy observed on the established UMSARS Part I scale."
• Why this matters: This quote is highly significant because it demonstrates that the drug’s benefit is not isolated to one type of test. Showing consistent efficacy across both a new (MuSyCA) and an established (UMSARS I) metric strengthens the overall scientific credibility of ATH434 as a disease-modifying therapy.

🔬 Program Status and Development Path 🚀

Alterity is highly focused on advancing ATH434 toward human use. The positive data from the Phase 2 trial, coupled with good biomarker results and a favorable safety profile, has accelerated its development status.

• Designations Received: ATH434 has received two crucial governmental designations:
  1. Fast Track Designation by the U.S. Food and Drug Administration (FDA).
  2. Orphan Drug Designation by both the FDA and the European Commission.
• Why this matters: These designations are critical fast tracks from regulators. They indicate that the FDA and European Commission recognize the drug's potential for treating rare diseases like MSA, generally simplifying and accelerating the approval path.
• Next Steps: Alterity is actively preparing to initiate a Phase 3 pivotal trial for MSA.

🏢 Alterity Therapeutics Company Overview 🌍

Alterity Therapeutics is a clinical-stage biotechnology company dedicated to finding new treatments for neurodegenerative diseases. The Company operates globally, based in Melbourne, Australia, and San Francisco, California, USA.

👉 Alterity's strategy is to develop disease-modifying therapies, meaning they aim to alter the course of the disease itself, rather than just managing symptoms.

📞 Contact and Resources 📧

For readers looking for more information, the company provided specific contacts and resources.

• Company Website: https://alteritytx.com
• Location: Melbourne, Australia, and San Francisco, California, USA.
• The full presentation and poster detailing the data are available on the Alterity Therapeutics website.

---

🧠 The Analogy

Imagine a disease like MSA is a leaking boat (the body) that is sinking (the decline). Most current medications are like small patches that only slow the leak from one specific pipe (treating only symptoms). ATH434, based on these Phase 2 results, is showing itself to be like a major, structural engineering project. It's not just plugging one leak; it's actively addressing the cause of the structural weakness (iron accumulation and protein buildup), which is required to stabilize the entire boat and slow the overall sinking process, making it a truly disease-modifying approach.

🧩 Final Takeaway

ATH434 demonstrated strong, consistent efficacy in slowing functional decline across multiple, validated measures for MSA. The positive Phase 2 data, coupled with prestigious regulatory designations (Fast Track/Orphan Drug), places the company in a strong position to initiate a critical Phase 3 pivotal trial.